ArticleCancer reports (Hoboken, N.J.)2022

Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab.

Naoki Kadota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.